Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Precigen, Inc. is one of them.

Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company developing precision genetic medicines for oncology, infectious diseases, and rare conditions. Its platforms include OmniCAR for adaptable CAR T-cell therapies and ActoBiotics for engineered bacterial delivery of therapeutics. The company recently achieved a major milestone with PAPZIMEOS (zopapogene imadenovec-drba), the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), a rare lung disease.

In early September 2025, Precigen, Inc. (NASDAQ:PGEN) secured up to $125 million through a non-dilutive financing deal with Pharmakon Advisors to support the commercialization of PAPZIMEOS in the U.S., international expansion, and exploration of pediatric and other HPV-related indications. This funding strengthens the company’s cash position without diluting shareholders, enabling accelerated growth and operational scaling.

Despite these positive developments, Precigen, Inc. (NASDAQ:PGEN) faces challenges, including a planned issuance of 143.81 million shares, which may exert short-term pressure due to potential dilution. Insider activity, including preferred stock conversions and share sales by director R.J. Kirk, also reflects ongoing capital structure shifts. The company continues to report operating losses as it invests heavily in commercialization infrastructure.

While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.